In the absence of a submission from the holder of the marketing authorisation, vildagliptin (Galvus®) cannot be endorsed for use within NHS Wales for the treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control; or in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.